MaaT Pharma Stock Forecast

Stock Price Forecast

According to 3 analysts polled by S&P Global, MaaT Pharma stock has a consensus rating of "Buy" and an average price target of €6.50. The average 1-year stock price forecast is 135.51% higher than the current stock price, while the lowest is €3.00 (+8.70%) and the highest is €10.00 (+262.32%).

Price Target: €6.50 (+135.51%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	€3.00	€6.50	€6.50	€10.00
Change	+8.70%	+135.51%	+135.51%	+262.32%

* Price targets were last updated on Mar 31, 2026.

Analyst Ratings

The average analyst rating for MaaT Pharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	3	4	4	4	1	2
Buy	1	1	1	1	1	0
Hold	0	0	0	0	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	4	5	5	5	3	3

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Clémence Thiers Stifel Nicolaus	Stifel Nicolaus	Buy Maintains €19.00	Buy	Maintains	€19.00	+588.41%	Mar 31, 2026
Christophe dombu Kepler Capital	Kepler Capital	Buy Maintains €17.00	Buy	Maintains	€17.00	+515.94%	Mar 31, 2026

Financial Forecast

Revenue This Year

9.75M

from 4.52M

115.53%

from 4.52M

Revenue Next Year

28.88M

from 9.75M

196.16%

from 9.75M

EPS This Year

-1.79

from -

EPS Next Year

-1.11

from -1.79

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	972.00K	1.43M	2.23M	3.22M	4.52M	9.75M
Revenue Growth	-	47.12%	55.80%	44.35%	40.67%	115.53%
Gross Profit	642.00K	788.00K	1.35M	1.60M	2.80M	9.44M
Gross Margin	66.05%	55.10%	60.59%	49.81%	61.80%	96.80%
Operating Income	-8.89M	-13.56M	-19.94M	-28.43M	-29.73M	-30.39M
Net Income	-9.02M	-13.71M	-19.72M	-28.90M	-31.06M	-31.69M
EPS	-	-	-	-	-	-1.79
Free Cash Flow	-4.99M	-8.04M	-11.13M	-12.25M	-14.16M	-28.23M
No. Analysts	-	-	-	-	-	5

EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is EUR.

Revenue Forecast

Revenue	2026	2027	2028
High	18.5M
Avg	9.8M
Low	4.0M

Revenue Growth

Revenue Growth	2026	2027	2028
High	309.4%
Avg	115.5%
Low	-11.6%

EPS Forecast

EPS	2026	2027	2028
High	-
Avg	-1.79
Low	-

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-